(NASDAQ: VXRT) Vaxart's forecast annual revenue growth rate of -35.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Vaxart's revenue in 2025 is $47,395,000.On average, 2 Wall Street analysts forecast VXRT's revenue for 2025 to be $5,511,584,315, with the lowest VXRT revenue forecast at $4,769,859,718, and the highest VXRT revenue forecast at $6,253,308,912. On average, 2 Wall Street analysts forecast VXRT's revenue for 2026 to be $3,069,598,718, with the lowest VXRT revenue forecast at $1,757,316,738, and the highest VXRT revenue forecast at $4,381,880,698.
In 2027, VXRT is forecast to generate $3,327,490,655 in revenue, with the lowest revenue forecast at $515,783,874 and the highest revenue forecast at $6,139,197,436.